New combo therapy aims to cut relapse in rare lymphoma
NCT ID NCT07450040
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug tislelizumab to standard chemotherapy and radiation can improve outcomes for people with early-stage NK/T-cell lymphoma, a rare blood cancer. About 60 adults aged 18 to 70 will receive the combination treatment. The goal is to see if this approach increases the number of patients whose tumors shrink significantly and helps prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL NK/T CELL LYMPHOMA, NASAL TYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
EENT hospital of Fudan University
Shanghai, China, 200000, China